PHARMA - Relationships

Relationships Table

Entities - Color - Target Drug Disease Lo Med Hi
Word 1
Word 1 Count
CAT1
CAT2
Word 2
Word 2 Count
Co-occurrence
Occurence-Centile
Correlation
Overlap-Metric
G-Metric
Melanoma Malignant 22 Disease Target Collagen 138,882 1 0.00 -0.98 0.05 0.56
Melanoma Malignant 22 Disease Disease Onychomycosis 2,201 1 0.00 -0.98 0.05 0.67
744.1 22 Target Disease Carcinoma 433,099 1 0.00 -0.98 0.05 0.54
744.1 22 Target Disease Acute Promyelocytic Leukemia 4,780 1 0.00 -0.98 0.05 0.64
744.1 22 Target Disease Chronic Obstructive Pulmonary Disease 27,780 1 0.00 -0.98 0.05 0.60
744.1 22 Target Disease Stroke 146,992 1 0.00 -0.98 0.05 0.56
744.1 22 Target Target Adiponectin 11,994 1 0.00 -0.98 0.05 0.62
744.1 22 Target Target 464.1 19 1 0.05 -0.95 0.05 0.83
744.1 22 Target Disease Hepatitis 163,842 1 0.00 -0.98 0.05 0.56
744.1 22 Target Disease Dyslipidemia 15,225 1 0.00 -0.98 0.05 0.61
744.1 22 Target Disease Leukemia 162,805 1 0.00 -0.98 0.05 0.56
744.1 22 Target Disease Liver Disease 49,817 1 0.00 -0.98 0.05 0.59
D-Alanyl-D-Alanine Carboxypeptidase 22 Target Target Dihydrofolate Reductase 5,563 1 0.00 -0.98 0.05 0.64
DC-CK1 22 Target Target Eotaxin 2,457 1 0.00 -0.98 0.05 0.66
DC-CK1 22 Target Target CCL5 2,002 1 0.00 -0.98 0.05 0.67
DC-CK1 22 Target Target CCL2 3,560 1 0.00 -0.98 0.05 0.65
DC-CK1 22 Target Disease Hepatitis 163,842 1 0.00 -0.98 0.05 0.56
DC-CK1 22 Target Target CXCL9 1,016 1 0.01 -0.98 0.05 0.69
DC-CK1 22 Target Disease Malaria 56,215 1 0.00 -0.98 0.05 0.58
DC-CK1 22 Target Target CCL3 1,427 1 0.01 -0.98 0.05 0.68
DC-CK1 22 Target Target CXCL11 526 1 0.01 -0.98 0.05 0.71
DC-CK1 22 Target Target CXCL3 145 1 0.02 -0.97 0.05 0.75
DC-CK1 22 Target Target CD34 24,598 1 0.00 -0.98 0.05 0.60
DC-CK1 22 Target Target CXCL10 2,386 1 0.00 -0.98 0.05 0.66
DC-CK1 22 Target Disease Septic Arthritis 4,121 1 0.00 -0.98 0.05 0.65
DC-CK1 22 Target Target CXCL2 750 1 0.01 -0.98 0.05 0.70
Alinia (Nitazoxanide)- FDA 22 Drug Disease Retinitis 9,116 1 0.00 -0.98 0.05 0.63
Alinia (Nitazoxanide)- FDA 22 Drug Disease Hepatitis 163,842 1 0.00 -0.98 0.05 0.56
Alinia (Nitazoxanide)- FDA 22 Drug Disease HIV/AIDS 20,397 1 0.00 -0.98 0.05 0.61
Alinia (Nitazoxanide)- FDA 22 Drug Disease Pain 409,851 1 0.00 -0.98 0.05 0.54
Alinia (Nitazoxanide)- FDA 22 Drug Drug Albendazole (Albenza)- FDA 5 1 0.10 -0.87 0.20 0.84
Alinia (Nitazoxanide)- FDA 22 Drug Disease Inflammation 252,734 1 0.00 -0.98 0.05 0.55
Steroid Delta-Isomerase 22 Target Target Activin A 2,048 1 0.00 -0.98 0.05 0.67
Drupanin 22 Drug Disease Ulcers 45,142 1 0.00 -0.98 0.05 0.59
Drupanin 22 Drug Disease Inflammation 252,734 1 0.00 -0.98 0.05 0.55
AMY2B 21 Target Target APOA2 118 1 0.02 -0.97 0.05 0.76
AMY2B 21 Target Disease Scoliosis 14,102 1 0.00 -0.98 0.05 0.62
AMY2B 21 Target Disease Psoriasis 26,882 1 0.00 -0.98 0.05 0.60
CAMK1D 21 Target Disease Diabetic Nephropathy 12,496 1 0.00 -0.98 0.05 0.62
Alefacept (Amevive)- FDA 21 Drug Drug Acitretin (Soriatane)- FDA 13 1 0.06 -0.94 0.08 0.84
Alefacept (Amevive)- FDA 21 Drug Disease Inflammation 252,734 1 0.00 -0.98 0.05 0.55
CAMK2D 21 Target Target CAMK4 43 1 0.03 -0.96 0.05 0.80
CAMK2D 21 Target Disease Inflammation 252,734 1 0.00 -0.98 0.05 0.55
CAMK2D 21 Target Target CYR61 539 1 0.01 -0.97 0.05 0.71
Cradle Cap 21 Disease Disease Disabilities 28,757 1 0.00 -0.98 0.05 0.60
Cradle Cap 21 Disease Disease Itching 5,798 1 0.00 -0.98 0.05 0.64
Cradle Cap 21 Disease Disease Asthma 109,610 1 0.00 -0.98 0.05 0.57
Amevive (Alefacept)- FDA 21 Drug Disease Inflammation 252,734 1 0.00 -0.98 0.05 0.55
CAMK2B 21 Target Target EGF 27,487 1 0.00 -0.98 0.05 0.60
CAMK2B 21 Target Disease Leukemia 162,805 1 0.00 -0.98 0.05 0.56
CAMK2B 21 Target Disease Breast Cancer 173,695 1 0.00 -0.98 0.05 0.56
CAMK2B 21 Target Disease Brain Tumors 16,749 1 0.00 -0.98 0.05 0.61
CAMK2B 21 Target Target BDNF 11,163 1 0.00 -0.98 0.05 0.62
CAMK2B 21 Target Disease Glioblastoma 17,933 1 0.00 -0.98 0.05 0.61
4-1BB Receptor 20 Target Disease Conjunctivitis 8,825 1 0.00 -0.97 0.05 0.63
4-1BB Receptor 20 Target Disease Tuberculosis 146,217 1 0.00 -0.97 0.05 0.56
4-1BB Receptor 20 Target Disease Lung Carcinoma 13,423 1 0.00 -0.97 0.05 0.62
4-1BB Receptor 20 Target Disease Influenza 67,933 1 0.00 -0.97 0.05 0.58
4-1BB Receptor 20 Target Disease Shock 134,031 1 0.00 -0.97 0.05 0.57
4-1BB Receptor 20 Target Target Collagen 138,882 1 0.00 -0.97 0.05 0.57
4-1BB Receptor 20 Target Disease Leukemia 162,805 1 0.00 -0.97 0.05 0.56
4-1BB Receptor 20 Target Disease Inflammation 252,734 1 0.00 -0.97 0.05 0.55
Cyclooxygenase-3 20 Target Target Collagen 138,882 1 0.00 -0.97 0.05 0.57
Cyclooxygenase-3 20 Target Target Platelet Activating Factor 9,915 1 0.00 -0.97 0.05 0.63
Cyclooxygenase-3 20 Target Disease Dementia 66,782 1 0.00 -0.97 0.05 0.58
BRSK1 20 Target Disease Cholesterol 182,390 1 0.00 -0.97 0.05 0.56
Ascorbic Acid (Vitamin C)- FDA 20 Drug Target Sphingomyelinase 3,060 1 0.00 -0.97 0.05 0.66
Ascorbic Acid (Vitamin C)- FDA 20 Drug Drug Aquasol A (Vitamin A)- FDA 46 1 0.03 -0.96 0.05 0.80
Ascorbic Acid (Vitamin C)- FDA 20 Drug Disease Leukemia 162,805 1 0.00 -0.97 0.05 0.56
Ascorbic Acid (Vitamin C)- FDA 20 Drug Disease Ulcers 45,142 1 0.00 -0.97 0.05 0.59
Ascorbic Acid (Vitamin C)- FDA 20 Drug Disease Heart Disease 118,291 1 0.00 -0.97 0.05 0.57
Dracorhodin 20 Drug Disease Pain 409,851 1 0.00 -0.97 0.05 0.54
Dracorhodin 20 Drug Disease Leukemia 162,805 1 0.00 -0.97 0.05 0.56
Dracorhodin 20 Drug Disease Breast Cancer 173,695 1 0.00 -0.97 0.05 0.56
Dropropizine 19 Drug Disease Sedation 27,984 1 0.00 -0.97 0.05 0.60
Doxacurium Chloride 19 Drug Drug Droperidol 1,957 1 0.01 -0.97 0.05 0.67
Doxacurium Chloride 19 Drug Disease Hypotension 42,123 1 0.00 -0.97 0.05 0.59
Complement Decay-Accelerating Factor 19 Target Target CEA 17,022 1 0.00 -0.97 0.05 0.61
Complement Decay-Accelerating Factor 19 Target Target Calmodulin 25,240 1 0.00 -0.97 0.05 0.60
Complement Decay-Accelerating Factor 19 Target Disease Infection 766,637 1 0.00 -0.97 0.05 0.53
Complement Decay-Accelerating Factor 19 Target Disease Chronic Lymphocytic Leukemia 11,642 1 0.00 -0.97 0.05 0.62
Complement Decay-Accelerating Factor 19 Target Target Collagen 138,882 1 0.00 -0.97 0.05 0.57
Complement Decay-Accelerating Factor 19 Target Disease Leukemia 162,805 1 0.00 -0.97 0.05 0.56
Complement Decay-Accelerating Factor 19 Target Disease Inflammation 252,734 1 0.00 -0.97 0.05 0.55
Kaad-Cyclopamine 19 Drug Disease Ovarian Cancer 33,996 1 0.00 -0.97 0.05 0.60
Kaad-Cyclopamine 19 Drug Disease Prostate Cancer 71,064 1 0.00 -0.97 0.05 0.58
Kaad-Cyclopamine 19 Drug Disease Basal Cell Carcinoma 7,953 1 0.00 -0.97 0.05 0.63
Kaad-Cyclopamine 19 Drug Target ERK1 18,374 1 0.00 -0.97 0.05 0.61
Kaad-Cyclopamine 19 Drug Target EGF 27,487 1 0.00 -0.97 0.05 0.60
Kaad-Cyclopamine 19 Drug Disease Lung Cancer 91,416 1 0.00 -0.97 0.05 0.58
Kaad-Cyclopamine 19 Drug Target Activin A 2,048 1 0.01 -0.97 0.05 0.67
AMAC-1 19 Target Disease Osteoarthritis 36,287 1 0.00 -0.97 0.05 0.60
AMAC-1 19 Target Disease Cancer 1,053,491 1 0.00 -0.97 0.05 0.53
AMAC-1 19 Target Target CCL4 5,638 1 0.00 -0.97 0.05 0.64
AMAC-1 19 Target Target CD14 9,941 1 0.00 -0.97 0.05 0.63
AMAC-1 19 Target Disease Infection 766,637 1 0.00 -0.97 0.05 0.53
AMAC-1 19 Target Target Eotaxin 2,457 1 0.00 -0.97 0.05 0.66
AMAC-1 19 Target Disease Arthritis 128,324 1 0.00 -0.97 0.05 0.57
AMAC-1 19 Target Target CCL2 3,560 1 0.00 -0.97 0.05 0.65
AMAC-1 19 Target Disease Rheumatoid Arthritis 78,952 1 0.00 -0.97 0.05 0.58